Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology.
about
Clozapine: a review of clinical practice guidelines and prescribing trendsAddressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment optionsRelapse prevention for schizophreniaImpact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophreniaSelf-limiting Atypical Antipsychotics-induced Edema: Clinical Cases and Systematic ReviewCanadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disordersIs adherence therapy an effective adjunct treatment for patients with schizophrenia spectrum disorders? A systematic review and meta-analysisThe quality of lactation studies including antipsychotics.Prescription practices in the treatment of first-episode schizophrenia spectrum disorders: data from the national RAISE-ETP studyAntipsychotic prescribing for vulnerable populations: a clinical audit at an acute Australian mental health unit at two-time points.Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review.Unheard voices: outcomes of tertiary care for treatment-refractory psychosis.The effects of vitamin and mineral supplementation on symptoms of schizophrenia: a systematic review and meta-analysis.Antipsychotics, mood stabilisers, and risk of violent crimeEfficacy and tolerability of quetiapine versus haloperidol in first-episode schizophrenia: a randomized clinical trial.BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP.Plasma amisulpride in relation to prescribed dose, clozapine augmentation, and other factors: data from a therapeutic drug monitoring service, 2002-2010.Predictors of psychiatric hospitalization during 6 months of maintenance treatment with olanzapine long-acting injection: post hoc analysis of a randomized, double-blind studyClozapine prescribing in a Canadian outpatient population.Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness.Use of second-generation antipsychotics in the acute inpatient management of schizophrenia in the Middle EastTreatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials.A Non-Interventional Naturalistic Study of the Prescription Patterns of Antipsychotics in Patients with Schizophrenia from the Spanish Province of Tarragona.Association of quetiapine with ischemic brain stem stroke: a case report and discussion.Cost-Effectiveness of Financial Incentives to Promote Adherence to Depot Antipsychotic Medication: Economic Evaluation of a Cluster-Randomised Controlled TrialLong-acting injectable antipsychotics for first-episode schizophrenia: the pros and cons.The Impact of Stakeholder Preferences on Service User Adherence to Treatments for Schizophrenia and Metabolic ComorbiditiesEpidemiology and Treatment Guidelines of Negative Symptoms in Schizo-phrenia in Central and Eastern Europe: A Literature Review.Assessing the burden of treatment-emergent adverse events associated with atypical antipsychotic medicationsAntipsychotic Prescribing Patterns in First-episode Schizophrenia: A Five-year ComparisonAssociation of cannabis use with hospital admission and antipsychotic treatment failure in first episode psychosis: an observational study"Care or control?": a qualitative study of staff experiences with outpatient commitment orders.A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project.QTc Prolongation in Patients Acutely Admitted to Hospital for Psychosis and Treated with Second Generation Antipsychotics.Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional studyPharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode.Relationship between Antidepressant Prescription Rates and Features of Schizophrenic Patients and Its Outcome in Schizophrenia Treatment.Prescribing pattern of clozapine and other antipsychotics for patients with first-episode psychosis: a cross-sectional survey of early intervention teams.Dosing and switching of paliperidone ER in patients with schizophrenia: recommendations for clinical practice.Schizophrenia--time to commit to policy change.
P2860
Q21260307-73FE7795-EA2E-4150-89CD-BC4437ECABE5Q22241447-71BCF5BC-9391-419E-8233-C448E6F88CA3Q24200778-7BE22F2E-E1C6-4F71-BC5D-AD13F325A62EQ24597701-C8E2C8C0-107A-41CB-885E-87D8D7496E57Q26747614-D8C91C0D-7B4D-4CB3-930D-BD1DE0E7718CQ27009995-C643AE53-7B15-41C4-89FF-A2F679075EE0Q28074062-0E180B70-6B95-40BB-A6FC-28C37FA567C7Q30248318-A7DD5D99-A868-4CCF-BD8B-F5C2D0C05BACQ30627430-EB424D16-CE59-41D7-9416-A2BE5C954018Q33560808-EBF9C1D6-EEB5-4D7A-B1CC-2C50389ED3B1Q33878816-5657F7E5-BD62-48D8-A0EB-8F6D813B826EQ33971222-53BC179E-15C8-473A-80B0-2FA630AC8C91Q34047983-0B6557FA-0F28-4E81-B5D7-1BE170462F1EQ34194840-CE7C77B8-9561-4EFB-AD69-02D3C353336CQ34242783-23A74A44-D112-4EEE-972F-CAB547FE0B7BQ34277168-D518B8FC-6128-4D4C-BEDB-569F2903A669Q34418688-5E420175-0050-4346-9ED3-0FBBA2429EEDQ34990923-FE60ADAE-0DBF-4F81-B2F1-59EB451C9FD1Q35073113-3242F8BD-FC8C-484C-A174-0A0F6FE8D24EQ35073474-9D9FA4DF-9E54-40D9-9C55-22156DAC0D94Q35320486-CEE2545E-771F-4F2C-85FC-E4BF5C840456Q35738997-CDF8C00B-DDEA-4241-9F96-B9802CB75093Q35795401-C14C8D51-F8E7-4A3D-99BF-0C0BD29F8DF3Q35948836-4814F306-7624-40D3-A027-89CAC1B687C2Q36137208-6F44149B-F931-4B41-AF99-E9973A12AB85Q36183650-32FD980E-FB13-4D1E-A1AA-C160647C09D9Q36193969-12FAFC00-ADAD-4B9E-A837-3BF5B5BC2A4DQ36232324-CC04ED83-3771-4865-B2B3-9CD47BA7A8B0Q36279100-BAB47067-A81F-409C-BDC8-355D8CB91937Q36325431-39856E2B-9E21-43D9-AF17-67363BE431D0Q36670457-21D4C52A-2EAB-41E4-B79E-DADADE13447FQ36840709-B23997F6-B346-43FB-A861-4D2463792F0EQ36852406-F0180457-7B91-4C4F-9B1D-A55276B0CA46Q37486960-2B0E5BBE-ABE0-4795-A134-D740700BFCF2Q37547469-06E761DA-267F-4EAB-8FEA-CDC7B7BD81DCQ37576827-8A80E5ED-F337-4E1D-933A-8E9938570C6BQ37703672-0BA101E0-FD4A-4BEC-9234-312383B7933CQ37705255-6688E11B-5A31-4764-A306-4564E4ABC8D5Q37714573-8C3C00D5-19C1-4E55-8FF6-61C8518700B2Q37727560-EE724D04-7CFB-4DE5-9ABF-641E5A16C3E8
P2860
Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Evidence-based guidelines for ...... iation for Psychopharmacology.
@ast
Evidence-based guidelines for ...... iation for Psychopharmacology.
@en
Evidence-based guidelines for ...... iation for Psychopharmacology.
@nl
type
label
Evidence-based guidelines for ...... iation for Psychopharmacology.
@ast
Evidence-based guidelines for ...... iation for Psychopharmacology.
@en
Evidence-based guidelines for ...... iation for Psychopharmacology.
@nl
prefLabel
Evidence-based guidelines for ...... iation for Psychopharmacology.
@ast
Evidence-based guidelines for ...... iation for Psychopharmacology.
@en
Evidence-based guidelines for ...... iation for Psychopharmacology.
@nl
P356
P1476
Evidence-based guidelines for ...... iation for Psychopharmacology.
@en
P2093
Schizophrenia Consensus Group of British Association for Psychopharmacology
Thomas R E Barnes
P304
P356
10.1177/0269881110391123
P407
P577
2011-02-03T00:00:00Z